Published in Cancer Weekly, March 6th, 1995
Randy A. Hock et al. report that many studies that have introduced class I and II MHC genes into tumor cells have used inefficient methods that required extensive cloning of the tumor cells before using them as vaccines ("Human Class II Major Histocompatibility Complex Gene Transfer into Murine Neuroblastoma Leads to Loss of Tumorigenicity, Immunity Against Subsequent Tumor Challenge, and Elimination of Microscopic Preestablished Tumors," Journal of Immunotherapy,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.